A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase I Study Evaluating Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of SOL-116 in Healthy Subjects and Patients With Rheumatoid Arthritis
Latest Information Update: 04 Mar 2025
At a glance
- Drugs SOL 116 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man
- Sponsors Lipum
Most Recent Events
- 25 Feb 2025 Positive Results published in the Lipum Media Release
- 06 Dec 2024 Status changed from active, no longer recruiting to completed.
- 24 Sep 2024 According to a Lipum media release, Company announces that the eighth and thus final patient with rheumatoid arthritis (RA) has been recruited and dosed with SOL-116 or placebo in the ongoing clinical phase 1 study.